Neuren Pharmaceuticals
$20.28Change from previous close: +0.70%Absolute change: +$0.14
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- $2.57B
- Enterprise value
- $2.28B
- P/E (trailing 12 months)
- 135.2
- Forward P/E
- 34.0
- Price/book
- 7.71
- Price/sales
- 37.0
- EV/EBITDA
- 164.5
- EV/revenue
- 32.9
Profitability and growth
- Gross margin
- 29.6%
- Operating margin
- 8.2%
- Net margin
- 29.1%
- ROE
- 6.2%
- ROA
- 2.6%
- Revenue growth (year over year)
- 17.3%
- Earnings growth (year over year)
- -67.3%
Financial health
- Total cash
- $286.54M
- Total debt
- $0
- Current ratio
- 46.5
- Quick ratio
- 44.6
Dividends
- Annual dividend per share
- $0.30
- Dividend yield
- 1.5%
- Payout ratio
- 0.0%
- Ex-dividend date
- September 15, 2026
Analysts and estimates
- Average price target
- $26.03
- Median price target
- $25.21
- High price target
- $28.90
- Low price target
- $24.50
- Analysts with a price target
- 6
- Forward EPS
- $0.60
- EPS estimate, current year
- $0.41
Shares and trading
- Beta
- 1.59
- Average volume
- 499.28K
- Shares outstanding
- 126.77M
- Float
- 109.86M
- Institutional ownership
- 23.8%
- Insider ownership
- 13.3%